44 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
9 Nov 23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
7:31am
, offset by an increase of $9.2 million of costs associated with preclinical studies and clinical trials for seralutinib.
General and Administrative (G
S-3
GOSS
Gossamer Bio Inc
18 Aug 23
Shelf registration
8:41am
fee of $19,678.47 paid on Form S-3ASR (File No. 333-274045) serves to offset the filing fee associated with this Form S-3.
8-K
EX-99.1
bnh8 vlrf
8 Aug 23
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.1
9zzm51w dds06j44a8g
3 Mar 22
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
4:02pm
DEFA14A
7tl7w
27 Apr 21
Additional proxy soliciting materials
4:18pm